1 2	Determinants of treatment success among drug-susceptible tuberculosis patients in Ghana: A prospective cohort study
3	
4	
5	Richard Delali Agbeko Djochie <sup>1</sup> , Berko Panyin Anto <sup>1, *</sup> , Mercy Naa Aduele Opare-Addo <sup>1</sup>
6 7	<sup>1</sup> Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
8	
9	
10	
11	
12	
13	
14	*Corresponding author
15	Email: <u>bpanto.pharm@knust.edu.gh</u> , <u>berkopanyin@hotmail.com</u> (BPA)
16	ORCID ID: 0000-0002-4673-4929
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	

## 30 Abstract

### 31 Background

Achieving optimal rates of success in tuberculosis treatment is vital not just for the individual patient's well-being but also for preventing the rise of drug-resistant tuberculosis strains. Unfavourable treatment outcomes pose significant challenges for healthcare systems worldwide. Identifying the factors that determine treatment success is crucial for implementing effective interventions that enhance treatment outcomes and contribute to the eradication of the disease. As a result, this study aimed to assess tuberculosis treatment outcomes and identify factors associated with treatment success.

### 39 Methods

40 Patients diagnosed with active tuberculosis were closely monitored from the start of their treatment 41 until its completion from January 2021 to June 2022. A data collection tool, developed using 42 Redcap and aligned with the study objectives, was utilized to gather demographic information, and 43 adverse reactions to antitubercular medicines and track the treatment outcomes of the participants. 44 The participants' quality of life was assessed using the Short-form 12 version 2 questionnaire at baseline, as well as at the end of the second and sixth months. Logistic regression was employed 45 46 to evaluate the association between various participant characteristics and treatment success, with 47 odds ratios used to quantify the strength of the associations.

### 48 **Results**

Among 378 participants, 77.3% had successful TB treatment, while 13.5% were lost to follow-up, 0.5% experienced treatment failure, and 8.7% died. Factors influencing treatment success included initial body weight, weight gain during treatment, HIV status, drug adverse reactions, and mental well-being at the beginning of treatment. Multivariate analysis showed that gaining at least 3kg during treatment and having no risk of depression at the beginning significantly increased the likelihood of successful treatment.

### 55 Conclusion

Patients with tuberculosis who experience compromised physical and mental health-related quality
 of life, encounter adverse reactions to antitubercular drugs and have concurrent HIV infection

58 should receive close monitoring and personalized interventions to improve their chances of 59 treatment success.

- 60 Keywords: Tuberculosis; treatment outcomes; health-related quality of life; Ghana
- 61

# 62 Introduction

63 Tuberculosis (TB) remains a pressing global health concern, affecting more than 10 million people 64 each year [1]. Despite being a preventable and treatable infection, TB ranks as the second deadliest 65 disease worldwide, only behind COVID-19 with 1.5 million fatalities in 2021 alone. The majority 66 of TB cases occur in low- and middle-income countries within the World Health Organisation's 67 (WHO) regions of South-East Asia, Africa, and the Western Pacific [1]. In 2021, Ghana reported 68 136 tuberculosis cases per 100,000 individuals, resulting in approximately 12,000 deaths attributed 69 to TB only and 3,700 TB/HIV coinfection deaths [2]. The impact of the COVID-19 pandemic on 70 healthcare services may have exacerbated this situation [1].

71 Tuberculosis treatment success rates exhibit significant variations across different countries and 72 regions. As of 2020, the global TB treatment success rate stood at 85%, short of the End TB Strategy target of 90% by 2025 [1]. In the United States, it was reported at 74%, while the African 73 74 Region averaged at 79% [1,3]. Adverse treatment outcomes for drug-susceptible TB cases pose a 75 significant challenge to healthcare systems worldwide. Achieving optimal treatment success rates 76 is not only essential for individual patient well-being but also for preventing the emergence of 77 drug-resistant TB strains. Despite free TB treatment accessibility in Ghana, the mortality rate 78 associated with this disease remains a concern. Since 2012, Ghana's TB treatment success rate has 79 plateaued at 84-85% [4,5], falling short of WHO's recommended target of 90% [6]. Studies in 80 Ghana, primarily retrospective in design, report varying treatment success rates across regions:

81 82.5% in the Volta region, 90.2% in the Central region, and 90.7% in the Greater Accra region
82 [7,8]. Prioritizing strategies to enhance treatment success is vital for the National Tuberculosis
83 Control Program (NTP) to reduce re-treatment needs, save costs, and lower morbidity and
84 mortality rates.

85 In lower- to medium-income countries, studies have identified factors contributing to unfavourable 86 TB treatment outcomes, including limited access to health logistics, nonadherence to treatment, 87 HIV coinfection, alcohol use, and drug abuse [9-11]. Other authors have also highlighted a 88 premature sense of recovery before completing the treatment, the absence of social support, 89 persistent stigma, and limited knowledge about TB as factors associated with adverse treatment 90 outcomes [12,13]. A systematic review found socioeconomic elements such as inadequate housing 91 (characterized by overcrowding and poor ventilation), malnutrition, and alcohol abuse as negative 92 influences on TB treatment outcomes [14].

Tuberculosis treatment success is influenced by a complex interplay of sociodemographic and clinical factors including low income, substance abuse, gender disparities, education level, unemployment, advanced age, membership in migratory communities, and the stigma surrounding TB, which collectively shape the outcomes of TB treatment programmes [14–16]. Evaluating TB treatment outcomes and identifying the root causes is essential for health authorities and policymakers.

While numerous studies have delved into the factors influencing low treatment success rates in Ghana, it's important to note that much work remains to be done in this field. Although some contributing factors to successful treatment outcomes, such as age and pretreatment weight, have been identified, there is still a critical need to expand the scope of research in order to gain a more comprehensive understanding of these complex dynamics [12,13,17]. Most of these studies,

104 predominantly retrospective in design, have yet to fully consider the impact of health-related 105 quality of life and the occurrence of adverse reactions to anti-TB drugs on treatment outcomes. 106 Therefore, there is a need for further research efforts to explore these factors in greater depth, 107 ultimately paying the way for more effective interventions to improve TB treatment success rates 108 in Ghana and similar settings. Consequently, this study aimed to assess treatment outcomes and 109 identify factors associated with success in patients with drug-susceptible TB taking into 110 consideration the impact of anti-TB adverse drug reactions and health-related quality of life. The 111 findings will contribute to the body of knowledge in TB management and provide evidence for 112 health managers and policymakers to develop tailored interventions for specific demographics. 113 These interventions aim to tackle the less-than-optimal rates of treatment success and ultimately 114 reduce the burden of TB within the country and similar global settings.

115

### 116 Methods

117 Study design and participants

118 This study was conducted in the Eastern and Ashanti Regions of Ghana, specifically at eight 119 tuberculosis treatment centres. These centres were chosen based on their consistent reporting of 120 the highest number of TB cases annually in their respective regions over the past five years. The 121 study sites consisted of three primary care hospitals and one regional referral hospital. The study 122 population included newly diagnosed TB patients who were eligible for drug treatment and ready 123 to initiate TB treatment. However, only patients who were 18 years of age or older, had access to 124 a mobile phone and provided their consent by signing a consent form were included. Conversely, 125 individuals with psychiatric conditions, liver or kidney impairment were excluded from the study.

To ensure sufficient statistical power with an 80% power analysis, a two-tailed test, an alpha level
of 0.05, and a medium effect size of 0.5, a minimum of 128 participants was required for this study.
However, considering potential non-responses and ensuring a diverse representation of
tuberculosis patients, 378 respondents were recruited.

### 130 Data collection and analysis

The data collection instrument utilized in this study was developed using REDCap, aligning with the study objectives. To ensure its reliability, the instrument underwent validation and was pretested in a hospital that was not part of the main study. The feedback received from the pretest was utilized to make necessary adjustments to the instrument.

Participant recruitment and data collection were conducted from 10<sup>th</sup> January 2021 to 15<sup>th</sup> April 135 136 2022. Trained research assistants called each participant, contacting them at least once a week to 137 inquire about any adverse effects resulting from their TB treatment. Additionally, any adverse drug 138 reactions (ADRs) recorded on the participants' TB treatment cards at the clinic were extracted. A 139 list of side effects associated with antitubercular drugs, documented in the literature, was used to 140 screen the participants. The Naranjo ADR Probability Scale was employed to determine the causal 141 relationship between the reported ADRs and the antitubercular drugs. Confirmation of a causal 142 relationship was established in scenarios where a patient experienced the same reaction after re-143 administration of the drug, when the reaction only occurred following drug administration, when 144 the reaction subsided or ceased after the administration of an antidote, and when the patient was 145 not taking any alternative medication known to cause the same reaction [18]. Only ADRs classified 146 as Certain (a score of  $\geq$ 9), Probable (a score of 5-8), or Possible (a score of 1-4) were included in 147 the analysis. The severity of antitubercular drug-related adverse reactions (ADRs) in participants 148 was assessed using Hartwig's ADR severity scale and categorized as severe (levels 5-7) if they led

to death, in-patient hospitalization, or prolonged hospital stay; moderate (levels 3-4) if they required withholding or discontinuation of anti-TB treatment and/or an antidote; and mild (levels 1-2) if they necessitated suspending anti-TB drugs without an antidote [19,20]. For analysis purposes, moderate-to-severe ADRs were grouped as major ADRs, while mild ADRs were considered minor ADRs.

154 The Short-form 12 version 2 questionnaire (SF-12v2) was employed in this study to assess the 155 participants' quality of life at baseline, as well as at the end of the second and sixth months. The 156 SF-12v2 survey consists of 12 items that measure various aspects of functioning and well-being 157 from the patient's perspective. This questionnaire is a validated and widely accepted tool for 158 evaluating the quality of life in individuals aged 18 and above, particularly in the context of chronic 159 illnesses [21,22]. The validity of the SF-12v2 as a health-related quality-of-life evaluation 160 instrument has also been confirmed among Ghanaian adults [23]. For comparative analysis, the 161 physical component summary (PCS) and mental component summary (MCS) scores were utilized in the current study [22]. A higher PCS or MCS score indicates a better quality of life. A minimum 162 163 clinically important difference (MCID) in quality of life at the end of treatment was defined as a 164 3-point increase in PCS or MCS scores while participants with an MCS score below 42 were 165 classified as experiencing depression [22].

### 166 Statistical analysis

Data cleansing was executed with Microsoft Excel 2016, and subsequently, data analysis was conducted using IBM SPSS Statistics (version 21). The findings were presented in the form of frequencies, percentages, and means with standard deviations. Chi-squared or Fisher's exact test, was applied to identify socio-demographic and clinical factors linked to treatment success. Logistic regression analysis, incorporating both crude and adjusted odds ratios, was utilised to gauge the

strength of any observed associations between patient characteristics and treatment success. Thethreshold for statistical significance was established at less than 0.05.

## 174 Ethical considerations

The study was conducted following ethical guidelines and was approved by two committees. The Ghana Health Service Ethics Review Committee granted approval with the number GHS-ERC 007/11/20 on January 2, 2021, and the Committee on Human Research, Publications, and Ethics of Kwame Nkrumah University of Science and Technology approved it with the number CHRPE/AP/171/21 on April 27, 2021.

Throughout the study, ethical principles were upheld. These principles included ensuring voluntary participation, beneficence, nonmaleficence, privacy, and confidentiality. Participants were fully informed and willingly chose to participate. They also provided written informed consent. Importantly, participants had the right to withdraw from the study at any time, and they were not required to provide a reason for doing so.

## 185 **Results**

### **186** Sociodemographic characteristics of participants

Among the 378 participants, the majority were male (67.2%), married (44.2%), and employed (75%), with a mean age of 45.3 ( $\pm$ 15.1) years. As shown in Table 1, 12.9% were illiterate, and a small proportion of participants had extrapulmonary TB (6.1%), were smokers (6.4%), consumed alcohol (25.4%), or were HIV-positive (25.7%).

191

192

Characteristics	Frequency <i>n</i>	Percentage o total
Age (years)		
18-25	26	6.9
26 - 35	84	22.2
36 - 45	90	23.8
46 - 55	90	23.8
56 - 65	49	13.0
<u>≥66</u>	39	10.3
Gender		
Male	254	67.2
Female	124	32.8
Marital status		
Married	167	44.2
Single	127	33.6
Divorced	41	10.9
Widowed	43	11.3
Employment status		11.5
Employed	289	76.5
Unemployed	89	23.5
Educational level		
Basic	230	60.9
Secondary	70	18.5
Tertiary	29	7.7
None	49	12.9
Type of TB		12.7
Pulmonary TB	350	92.6
Extra-pulmonary TB	23	6.1
Both	5	1.3
Smoking status	<u>_</u>	1.5
Smoker	24	6.4
Nonsmoker	354	93.6
Alcohol use		/5.0
Yes	96	25.4
No	282	74.6
HIV status	202	/ च.0
HIV positive	97	25.7
HIV negative	275	72.8
HIV status unknown	6	1.5
Baseline HRQOL	0	1.5
Depression	97	25.7
Physical impairment	298	78.8
ADR Status	270	/0.0
No ADR	198	50 1
		52.4
Minor ADR	68	18.0
Major ADR	$\frac{112}{1000}$	29.6

### 193 Table 1 Sociodemographic and clinical characteristics of study participants

194 TB = Tuberculosis, HIV = Human immune-deficiency virus, ADR = Adverse drug reaction, HRQOL = health-related quality of life

### **Treatment outcomes of study participants**

197 The distribution of tuberculosis treatment outcomes among the study participants was as follows: 198 44.2% were cured, 33.1% completed their therapy, 13.5% were lost to follow-up, 8.7% died, and 199 0.5% were classified as treatment failures. Therefore, the overall treatment success rate in this 200 study was 77.3%.

201 As illustrated in Table 2, gender did not significantly affect treatment success, with 78.7% of males 202 and 74.2% of females achieving successful treatment (p = 0.322). However, a notable difference 203 was observed based on participants' baseline weight, where those with a weight of at least 53kg 204 had a significantly higher success rate (83.6%) compared to those with less weight (72.6%) (p = 205 0.011). Furthermore, the amount of weight gained during treatment had a substantial influence on 206 treatment success. Participants who gained a minimum of 3kg during treatment demonstrated a 207 remarkable success rate of 90.9%, while those who gained less than 3kg had a success rate of 208 65.5% (p < 0.001). Other factors, such as alcohol use, tobacco smoking, and the initiation of Highly 209 Active Antiretroviral Treatment (HAART) before tuberculosis, did not show statistically 210 significant associations with treatment success. However, participants with HIV-negative status 211 exhibited a significantly higher success rate (81.8%) compared to those with HIV-positive status 212 (64.9%) (p = 0.002). Additionally, the type of HIV infection (HIV-1, HIV-2, or both) had a 213 significant impact on treatment success, with HIV-2-infected participants demonstrating the 214 lowest success rate (57.1%) compared to the other groups (p = 0.011). Regarding the site of TB 215 infection, those with extrapulmonary TB achieved a 100% success rate, while participants with 216 pulmonary TB had a success rate of 75.4% (p = 0.003).

217

#### 218 Table 2 Association between patient characteristics and treatment success

Parameter	Number of participants	% of patients with treatment success	p-value
Gender		success	
Male	254	78.7	0.322
Female	124	74.2	0.522
Weight at baseline		,	
< 53kg	219	72.6	0.011
$\geq$ 53kg	159	83.6	0.011
Total weight gained			
< 3kg	174	65.5	< 0.001
$\geq 3 \text{kg}$	170	90.9	
Alcohol use			
Yes	96	72.9	0.241
No	282	78.7	J. <b>_</b> . 1
Tobacco smoking			
Yes	24	83.3	0.462
No	354	76.8	
HIV status			
HIV-positive	97	64.9	
HIV-negative	275	81.8	0.002
HIV status unknown	6	66.7	
НІ  Туре			
HIV-1	83	69.9	
HIV-2	7	57.1	0.011
Both HIV-1 & 2	7	14.3	
Site of TB infection			
Pulmonary	350	75.4	0.003
Extra-pulmonary	28	100.0	
HAART started before TB			
Yes	84	72.0	0.133
No	13	57.4	
ADR status			
No ADR	198	77.3	0.001
At least one ADR	180	77.2	0.991
Physical HRQOL at baseline			
Good physical health	76	88.8	0.006
Poor physical health	302	74.2	
Mental HRQOL at baseline			
Good mental health	281	80.2	0.026
Poor mental health	97	69.1	

WHO=World Health Organization; MCS=mean component summary; PCS=physical component summary; HIV=human immunodeficiency virus; HAART=highly active antiretroviral treatment; TB=tuberculosis; ADR = adverse drug reaction.

221

222

The presence or absence of adverse reactions to antitubercular drugs didn't make a significant difference in the success rates of treatment. The success rates were quite similar at 77.3% for those with adverse reactions and 77.2% for those without (p = 0.991). Additionally, the severity of these adverse reactions also did not affect the treatment outcomes. However, when looking at participants who experienced minor and major adverse reactions

separately, their success rates were 80.9% and 75.0%, respectively (p = 0.362). So, the severity of the adverse reactions didn't seem to impact success significantly.

On the other hand, the initial physical health of participants did have a notable impact on the treatment's success. Those in good physical health had a significantly higher success rate of 88.8%, compared to those in poor physical health, who had a success rate of 74.2% (p = 0.006). Similarly, the initial mental health of participants also played a role, with those in good mental health achieving a higher success rate of 80.2%, while those in poor mental health had a lower success rate of 69.1% (p = 0.026).

### 236 **Determinants of treatment success**

The robustness of the relationships between patient characteristics and the success of treatment, as depicted in Table 3, reveals significant findings. Participants with a baseline weight above 53 kg exhibited 1.9 times higher odds of achieving treatment success compared to those with a weight of 53 kg or less, with an odds ratio (OR) of 1.9 (95% CI: 1.2 - 3.2, p = 0.012). Additionally, individuals who gained at least 3 kg during the course of treatment demonstrated significantly increased odds of treatment success, with an OR of 4.5 (95% CI: 2.2 - 9.0, p < 0.001).

HIV status played a crucial role in treatment outcomes. HIV-negative participants had more than
twice the odds of achieving treatment success compared to their HIV-positive counterparts, with

an OR of 2.4 (95% CI: 1.4 - 4.1, p < 0.001). Furthermore, participants with HIV-1 infection

showed over four times the odds of success compared to those with HIV-2, with an OR of 4.2

247 (95% CI: 1.3 – 3.7, p = 0.019).

248

249 Table 3 The effect of participants' characteristics on the odds of having treatment success

Patient characteristics	Treatment success		
-	OR	95% CI	<i>P</i> -value
Weight at baseline			
$\leq$ 53 kg	1		
>53 kg	1.9	1.2 - 3.2	0.012
Total weight gained during treatment			
<3 kg	1		
$\geq 3 \text{ kg}$	4.5	2.2 - 9.0	< 0.001
HIV status			
HIV-positive	1		
HIV-negative	2.4	1.4 - 4.1	< 0.001
Type of HIV			
HÍV-2	1		
HIV-1	4.2	1.3 - 3.7	0.019
Physical HRQOL at baseline			
Poor physical health	1		
Good physical health	2.5	1.2 - 5.3	0.014
Mental HRQOL at baseline			
Poor mental health	1		
Good mental health	1.8	1.1 - 3.0	0.027
Gastrointestinal ADR			
Yes	1		
No	1.8	1.1 - 3.0	0.019
Hepatobiliary system ADR			
Yes	1		
No	21.8	2.6 - 183.0	0.005

250 ADR = adverse drug reaction; HRQOL = health-related quality of life; HIV = human immunodeficiency virus

251

252 The physical and mental HRQOL at the beginning of treatment significantly influenced outcomes.

253 Participants in good physical health had three times higher odds of treatment success compared to

those in poor physical health, with an OR of 2.5 (95% CI: 1.2 - 5.3, p = 0.014). Similarly,

individuals in good mental health exhibited nearly twice the odds of success compared to those in poor mental health, with an OR of 1.8 (95% CI: 1.1 - 3.0, p = 0.027).

Furthermore, antitubercular ADRs had varying impacts on treatment success. While the severity of ADRs did not significantly affect treatment outcomes, participants who did not experience gastrointestinal ADRs had twice the odds of treatment success (OR = 1.8, 95% CI: 1.1 - 3.0, p =0.019), and those without hepatobiliary system ADRs had a strikingly higher likelihood of treatment success, with odds almost 22 times greater than those with such ADRs (OR = 21.8, 95%CI: 2.6 - 183.0, p = 0.005).

A multivariate analysis considering all statistically significant factors related to treatment success indicated that gaining at least 3kg of body weight at the end of treatment (p = 0.004) and not being at risk of depression at the beginning of treatment (p = 0.016) remained significantly associated with a successful treatment outcome.

While this study observed that a higher proportion of males, non-smokers, non-drinkers, and patients receiving Highly Active Antiretroviral Treatment (HAART) tended to have improved treatment outcomes, it's important to note that these distinctions did not attain statistical significance.

# 271 **Discussion**

The TB treatment success rate in this study stood at 77.3%, comprising 44.2% of participants who were cured and 33.1% who completed their treatment. This rate fell below both the national average of 84% [6] and the WHO's target of 90% [8]. It also trailed behind the success rates of 81.8%, 81.0% and 90.2% reported in studies conducted in Somalia [24], India [26], and another study within the Central region of Ghana [7]. Nonetheless, it exceeded the success rates reported

in certain Ethiopian studies (71.4% and 60.1%) [25,27] as well as the 68.5% reported by a tenyear retrospective study conducted in the Ashanti Region of Ghana [17].

279 Among the participants, 22.8% experienced adverse treatment outcomes, including 13.5% who 280 were lost to follow-up, 8.7% who died, and 0.5% who had treatment failure. The loss to follow-up 281 rate in this study was similar to the 6.2% observed in Somalia [24] and the 8% reported in Ethiopia 282 [25]. However, it was lower than the 21.3% found in another Ethiopian study [27] and the 12.5% 283 in an Indian study [26] but higher than the 0.9% reported in another Ghanaian study [7]. Defaulting 284 on TB treatment not only worsens symptoms to the point of requiring hospitalization but also poses 285 a public health risk by potentially spreading drug-resistant strains of Mycobacterium. Therefore, 286 it is crucial to provide comprehensive pre-treatment adherence counselling and continue 287 reinforcing it during clinic visits [28].

288 Among the 33 participants who died during TB treatment, 63.6% (n=21) were HIV-positive. The 289 TB death rate (8.7%) observed in this study was lower than the 10% target set by the TB strategic 290 plan [29], 17.7% reported in Ethiopia [27], and 10.1% in another Ethiopian study [30]. However, 291 it was higher than the 4.17% in a Pakistani study [31] and the 2% reported in India [26]. 292 Tuberculosis infection accelerates the progression of acquired immune deficiency syndrome 293 (AIDS) in HIV-positive individuals [32], making them more vulnerable to opportunistic infections 294 that require additional treatment. In contrast, tuberculosis patients without HIV infection generally 295 achieve better treatment outcomes [10,24,27,30,33]. This is due to the detrimental effect of HIV 296 infection on CD4 cell counts and overall immunity, which impairs successful treatment. The higher 297 pill burden and potential drug interactions associated with HIV treatment contribute to increased 298 nonadherence rates and lower rates of treatment success.

Importantly, the type of HIV infection influences treatment outcomes, with HIV-1 patients having more than double the odds of achieving successful treatment outcomes compared to those with HIV-2 infection. This finding aligns with a prospective study conducted in Guinea Bissau, which found that HIV-infected patients showed greater clinical severity of tuberculosis [32]. It underscores the significance of promptly diagnosing and treating HIV in tuberculosis patients, as well as offering continuous adherence support and psychological counselling during treatment for individuals living with HIV, to ensure treatment success.

Unlike certain studies conducted in the African region [25,27], this study reveals a notable positive correlation between extrapulmonary TB and treatment success. In our study, all participants with extrapulmonary TB achieved successful treatment outcomes, aligning with findings from analogous studies conducted in Bhutan and Ethiopia [34,35]. Further research is needed to comprehensively understand the relationship between the type of TB infection and treatment success.

312 The importance of increasing body weight in TB patients through proper nutrition to improve their 313 physical health and treatment outcomes has been widely recognized [36–39]. This study confirms 314 that patients who had a baseline weight of over 53kg or gained at least 3kg of body weight during 315 treatment achieved successful outcomes, consistent with findings from Peru and Ethiopia [39,40]. 316 The positive impact of weight gain on treatment outcomes can be attributed to improved nutrition, 317 which strengthens the immune system and supports the healing process. Therefore, offering 318 nutritional support to vulnerable TB patients, such as those experiencing homelessness or living 319 in impoverished households, could significantly enhance their chances of treatment success.

320 Participants who did not have physical impairment at the beginning of treatment had nearly three321 times higher odds of achieving a successful treatment outcome compared to those with physical

impairment. Similarly, patients without a risk of depression at baseline had almost twice the odds of treatment success. It is crucial for healthcare workers dealing with TB to identify such patients and provide them with adequate counselling to address the psychosocial and emotional challenges associated with the disease. Additionally, effectively managing comorbidities that could cause physical impairment can improve patients' physical strength and increase their likelihood of treatment success. Implementing interventions to eliminate stigma within communities is also highly recommended.

329 We found no significant association between the rate of treatment success among participants who 330 did not experience any anti-TB drug reactions and those who had at least one ADR. Moreover, the 331 difference in treatment success rate among participants who had minor ADRs and those who had 332 major ADRs was not statistically significant. This suggests that the severity of adverse drug 333 reactions did not appear to significantly influence treatment outcomes in this study. However, it 334 was observed that participants who did not develop any gastrointestinal adverse drug reactions had 335 twice the odds of treatment success compared to those who did. Similarly, participants who did 336 not experience any hepatobiliary system adverse drug reactions had 22 times the odds of treatment 337 success compared to those who did. These findings align with two prospective studies conducted 338 in India and China, which also reported that the absence of antitubercular adverse drug reactions 339 significantly correlated with treatment success [41,42]. To fully understand the role of 340 gastrointestinal and hepatobiliary ADRs in determining TB treatment success, further research is 341 required.

# 342 **Conclusion**

This study highlights several key factors that significantly influence treatment outcomes in drugsusceptible tuberculosis cases: including baseline weight, weight gain during treatment, HIV

- 345 status, mental and physical health, and the presence of gastrointestinal and hepatobiliary system
- 346 adverse drug reactions. Recognizing and addressing these determinants can guide healthcare
- 347 professionals in tailoring interventions to enhance treatment success rates, ultimately contributing
- to the battle against tuberculosis.

# 349 Acknowledgement

- 350 The authors are grateful to the managers of the hospitals in the study sites and all TB patients
- 351 who willingly participated in the study.

# 352 **References**

- 353 [1] WHO. Global TB Report 2022. Geneva: 2022.
- WHO. Tuberculosis profile: Ghana 2021.
  https://worldhealthorg.shinyapps.io/tb\_profiles/?\_inputs\_&entity\_type=%22country%22&
  lan=%22EN%22&iso2=%22GH%22 (accessed January 4, 2023).
- Teferi MY, El-Khatib Z, Boltena MT, Andualem AT, Asamoah BO, Biru M, et al.
   Tuberculosis treatment outcome and predictors in Africa: a systematic review and metaanalysis. Int J Environ Res Public Health 2021;18:10678.
- Palmer VE. Ghana: Strategic Focus. CDC Division of Global HIV & TB Country Profile
   2022. https://www.cdc.gov/globalhivtb/where-we-work/Ghana.pdf (accessed September
   22, 2022).
- 363 [5] WHO. Global Tuberculosis Report 2019. Geneva: 2019.
- 364 [6] WHO. The End TB Strategy. Geneva: 2015.
- 365 [7] Otchere J, Ayi I, Tetteh AK, Bimi L, Agyarko E. An Evaluation of Treatment Outcomes
  366 in a Cohort of Clients on the DOTS Strategy, 2012–2016. Tuberc Res Treat 2018.
  367 https://doi.org/10.1155/2018/4287842.
- 368 [8] Ohene SA, Fordah S, Dela Boni P. Childhood tuberculosis and treatment outcomes in
  369 Accra: A retrospective analysis. BMC Infect Dis 2019;19:1–9.
  370 https://doi.org/10.1186/S12879-019-4392-6/TABLES/4.
- [9] Chaves Torres NM, Quijano Rodríguez JJ, Porras Andrade PS, Arriaga MB, Netto EM.
   Factors predictive of the success of tuberculosis treatment: A systematic review with
   meta-analysis. PLoS One 2019;14:e0226507.

Getie A, Alemnew B. Tuberculosis treatment outcomes and associated factors among
patients treated at Woldia General Hospital in Northeast Ethiopia: An institution-based
cross-sectional study. Infect Drug Resist 2020;13:3423–9.
https://doi.org/10.2147/IDR.S275568.

- 378 [11] Amo-Adjei J, Awusabo-Asare K. Reflections on tuberculosis diagnosis and treatment
  379 outcomes in Ghana. Archives of Public Health 2013;71:22. https://doi.org/10.1186/2049380 3258-71-22.
- [12] Appiah MA, Arthur JA, Gborgblorvor D, Asampong E, Kye-Duodu G, Kamau EM, et al.
  Barriers to tuberculosis treatment adherence in high-burden tuberculosis settings in
  Ashanti region, Ghana: a qualitative study from patient's perspective. BMC Public Health
  2023;23:1317.
- 385 [13] Osei E, Oppong S, Adanfo D, Doepe BA, Owusu A, Kupour AG, et al. Reflecting on
  386 tuberculosis case notification and treatment outcomes in the Volta region of Ghana: a
  387 retrospective pool analysis of a multicentre cohort from 2013 to 2017. Glob Health Res
  388 Policy 2019;4:1–13. https://doi.org/10.1186/S41256-019-0128-9/TABLES/3.
- 389 [14] Lee J-Y, Kwon N, Goo G, Cho S. Inadequate housing and pulmonary tuberculosis: a
  390 systematic review. BMC Public Health 2022;22:1–12.
- [15] Nidoi J, Muttamba W, Walusimbi S, Imoko JF, Lochoro P, Ictho J, et al. Impact of socio economic factors on Tuberculosis treatment outcomes in north-eastern Uganda: a mixed
   methods study. BMC Public Health 2021;21:1–16.
- 394 [16] Pradipta IS, Idrus LR, Probandari A, Lestari BW, Diantini A, Alffenaar J-WC, et al.
  395 Barriers and strategies to successful tuberculosis treatment in a high-burden tuberculosis
  396 setting: a qualitative study from the patient's perspective. BMC Public Health 2021;21:1–
  397 12.
- 398 [17] Agyare SA, Osei FA, Odoom SF, Mensah NK, Amanor E, Martyn-Dickens C, et al.
  399 Treatment Outcomes and Associated Factors in Tuberculosis Patients at Atwima
  400 Nwabiagya District, Ashanti Region, Ghana: A Ten-Year Retrospective Study. Tuberc
  401 Res Treat 2021;2021:1–9. https://doi.org/10.1155/2021/9952806.
- 402 [18] Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for
  403 estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–
  404 45.
- 405 [19] Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting
  406 adverse drug reactions. Am J Hosp Pharm 1992;49:2229–32.
- 407 [20] Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to
   408 terminology, documentation, and reporting. Ann Intern Med 2004;140:795–801.
- 409 [21] Huo T, Guo Y, Shenkman E, Muller K. Assessing the reliability of the short form 12 (SF410 12) health survey in adults with mental health conditions: a report from the wellness

411 412		incentive and navigation (WIN) study. Health Qual Life Outcomes 2018;16:34. https://doi.org/10.1186/s12955-018-0858-2.
413 414	[22]	Bohannon R, Maljanian R, Landes M. Test-retest reliability of short form (SF)-12 component scores of patients with stroke. Int J Rehabil Res 2004;27:149–50.
415 416 417	[23]	Galenkamp H, Stronks K, Mokkink LB, Derks EM. Measurement invariance of the SF-12 among different demographic groups: The HELIUS study. PLoS One 2018;13:1–19. https://doi.org/10.1371/journal.pone.0203483.
418 419 420 421	[24]	Ali MK, Karanja S, Karama M. Factors associated with tuberculosis treatment outcomes among tuberculosis patients attending tuberculosis treatment centres in 2016-2017 in Mogadishu, Somalia. Pan African Medical Journal 2017;28:1–14. https://doi.org/10.11604/pamj.2017.28.197.13439.
422 423 424	[25]	Abebe T, Angamo MT. Treatment outcomes and associated factors among tuberculosis patients in Southwest Ethiopia. Gulhane Medical Journal 2015;57:397–407. https://doi.org/10.5455/gulhane.161306.
425 426 427	[26]	Jain S, Bhagyalaxmi A, Kadri A. Defaulter rate and associated factors among the Tuberculosis patients treated under DOTS in Ahmedabad City. Indian J Prev Soc Med 2012;43:158–64.
428 429 430	[27]	Biruk S, Yimam B, Amdie FZ, Biruk M, Abrha H. Treatment Outcomes of Tuberculosis and Associated Factors in an Ethiopian University Hospital. Adv Public Health 2016. https://doi.org/10.1155/2016/8504629.
431 432 433 434	[28]	Muture BN, Keraka MN, Kimuu PK, Kabiru EW, Ombeka VO, Oguya F. Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: A case-control study. BMC Public Health 2011;11. https://doi.org/10.1186/1471-2458-11-696.
435 436	[29]	MOH. The National Tuberculosis Health Sector Strategic Plan for Ghana: 2015-2020. Ministry of Health 2015:1–132.
437 438 439	[30]	Zenebe T, Tefera E. Tuberculosis treatment outcome and associated factors among smear- positive pulmonary tuberculosis patients in Afar, Eastern Ethiopia: a retrospective study. Braz J Infect Dis 2016;20:635–6.
440 441 442	[31]	Tripathi SB, Kapadia VK. Treatment Outcome of Tuberculosis in HIV Seropositive Patients : an Experience of Southeast Region of Ahmedabad. National Journal of Community Medicine 2015;6:462–5.
443 444 445 446	[32]	Wejse C, Patsche CB, Kühle A, Bamba FJV, Mendes MS, Lemvik G, et al. Impact of HIV-1, HIV-2, and HIV-1+2 dual infection on the outcome of tuberculosis. International Journal of Infectious Diseases 2015;32:128–34. https://doi.org/10.1016/J.IJID.2014.12.015.

Eshetie S, Gizachew M, Alebel A, Van Soolingen D. Tuberculosis treatment outcomes in
Ethiopia from 2003 to 2016, and impact of HIV co-infection and prior drug exposure: A
systematic review and meta-analysis. PLoS One 2018;13:1–18.
https://doi.org/10.1371/journal.pone.0194675.

- 451 [34] Berhe G, Enquselassie F, Aseffa A. Treatment outcome of smear-positive pulmonary
  452 tuberculosis patients in Tigray Region, Northern Ethiopia. BMC Public Health 2012;12:1–
  453 9.
- [35] Jamtsho T, Harries AD, Malhotra S, Wangchuk D, Dophu U, Dorji T, et al. The burden
  and treatment outcomes of extra-pulmonary tuberculosis in Bhutan. Public Health Action
  2013;3:38–42.
- 457 [36] Filate M, Mehari Z, Alemu YM. Longitudinal body weight and sputum conversion in 458 patients with tuberculosis, Southwest Ethiopia: a retrospective follow-up study. BMJ 459 Open 2018;8:e019076. https://doi.org/10.1136/BMJOPEN-2017-019076.
- 460 [37] Alemu A, Bitew ZW, Worku T. Poor treatment outcome and its predictors among drug461 resistant tuberculosis patients in Ethiopia: A systematic review and meta-analysis.
  462 International Journal of Infectious Diseases 2020;98:420–39.
  463 https://doi.org/10.1016/J.IJID.2020.05.087.
- 464 [38] Gler MT, Guilatco R, Caoili JC, Ershova J, Cegielski P, Johnson JL. Weight Gain and
  465 Response to Treatment for Multidrug-Resistant Tuberculosis. Am J Trop Med Hyg
  466 2013;89:943. https://doi.org/10.4269/AJTMH.13-0011.
- 467 [39] Sahile Z, Tezera R, Mariam DH, Collins J, Ali JH. Nutritional status and TB treatment
  468 outcomes in Addis Ababa, Ethiopia: An ambi-directional cohort study. PLoS One
  469 2021;16:e0247945. https://doi.org/10.1371/JOURNAL.PONE.0247945.
- [40] Krapp F, Véliz JC, Cornejo E, Gotuzzo E, Seas C. Bodyweight gain to predict treatment
  outcome in patients with pulmonary tuberculosis in Peru. The International Journal of
  Tuberculosis and Lung Disease 2008;12:1153–9.
- [41] Lv X, Tang S, Xia Y, Wang X, Yuan Y, Hu D, et al. Adverse Reactions Due to Directly
  Observed Treatment Strategy Therapy in Chinese Tuberculosis Patients: A Prospective
  Study. PLoS One 2013;8:e65037. https://doi.org/10.1371/JOURNAL.PONE.0065037.
- [42] Nagpal M, Devgun P, Kalra RK, Chawla N. Study on the adverse effects affecting
  treatment outcome in smear-positive tuberculosis patients under DOTS in Amritsar City.
  Int J Community Med Public Health 2018;5:801–5. https://doi.org/10.18203/23946040.ijcmph20180272.
- [43] Kassa JI, Dedefo MG, Korsa AT, Dibessa TT. Factors Affecting Treatment Outcome of
  Tuberculosis among Tuberculosis Patients in West Ethiopia. J Bioanal Biomed 2018.
  https://doi.org/10.4172/1948-593x.1000200.

483 [44] Thiruvengadam K, Swaminathan S, Jayapal L, Vedhachalam C, Dusthackeer A, Agibothu

- 484 Kupparam HK, et al. Factors Influencing Tuberculosis Treatment Outcome in Adult
- 485 Patients Treated with Thrice-Weekly Regimens in India. Antimicrob Agents Chemother
- 486 2017;61:1–12. https://doi.org/10.1128/aac.02464-16.

487